PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Dual antiplatelet therapy is essential in patients following ST-Elevation myocardial
infarction (STEMI) with percutaneous coronary intervention (PCI) and drug eluting stent
implantation. Current guidelines recommend prasugrel and ticagrelor in patients with STEMI
undergoing primary PPCI. We sought to investigate the superiority antiplatelet effect in
terms of PR level of loading dose (LD) of Prasugrel (60 mg) versus LD of Ticagrelor (180 mg)
in diabetic patients with STEMI undergoing primary PCI at 1 and 2 hours post drug
administration. Secondary end-points will be: PR level measured at 6 and 12 hours post study
drugs administrationin hospital. All consecutive diabetic patients with STEMI undergoing PPCI
with stent implantation will be considered for PR assessment at 1-2-6-12 h after the drug LD
administration. All patients must will be naïve for platelet P2Y12 receptor inhibition
therapy. A subanalysis will be performed between two study groups according to insulin
treatment.